Apeiron Biologics (dinutuximab beta) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Apeiron Biologics (dinutuximab beta) General Information

Description

A global commercialization rights to the oncology product Isqette (dinutuximab beta). Dinutuximab beta is currently used as part of the regimen for the treatment of high risk neuroblastoma in Europe and is available under a managed access program.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Vienna
  • Austria
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • Vienna
  • Austria

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apeiron Biologics (dinutuximab beta) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Apeiron Biologics (dinutuximab beta)‘s full profile, request access.

Request a free trial

Apeiron Biologics (dinutuximab beta) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Apeiron Biologics (dinutuximab beta)‘s full profile, request access.

Request a free trial

Apeiron Biologics (dinutuximab beta) FAQs

  • Where is Apeiron Biologics (dinutuximab beta) headquartered?

    Apeiron Biologics (dinutuximab beta) is headquartered in Vienna, Austria.

  • What industry is Apeiron Biologics (dinutuximab beta) in?

    Apeiron Biologics (dinutuximab beta)’s primary industry is Buildings and Property.

  • Is Apeiron Biologics (dinutuximab beta) a private or public company?

    Apeiron Biologics (dinutuximab beta) is a Private company.

  • What is Apeiron Biologics (dinutuximab beta)’s current revenue?

    The current revenue for Apeiron Biologics (dinutuximab beta) is .

  • Who are Apeiron Biologics (dinutuximab beta)’s investors?

    APEIRON Biologics has invested in Apeiron Biologics (dinutuximab beta).

  • When was Apeiron Biologics (dinutuximab beta) acquired?

    Apeiron Biologics (dinutuximab beta) was acquired on 04-Oct-2016.

  • Who acquired Apeiron Biologics (dinutuximab beta)?

    Apeiron Biologics (dinutuximab beta) was acquired by EUSA Pharma (UK).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process